G Argiles
Overview
Explore the profile of G Argiles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
882
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Argiles G, Arnold D, Cervantes A
Ann Oncol
. 2025 Feb;
36(3):231-232.
PMID: 39984220
No abstract available.
2.
Lenz H, Argiles G, de Jonge M, Yaeger R, Doi T, El-Khoueiry A, et al.
ESMO Open
. 2024 Dec;
9(11):103729.
PMID: 39617530
Background: Aberrant Wnt pathway signaling has been implicated in the development of many cancers. Targeting of low-density lipoprotein receptor-related protein 5/6 (LRP5/6) co-receptors inhibits Wnt signaling and may be a...
3.
Martini G, Belli V, Napolitano S, Ciaramella V, Ciardiello D, Belli A, et al.
ESMO Open
. 2023 Apr;
8(3):101198.
PMID: 37119788
Background: Metastatic colorectal cancer (mCRC) patients tend to have modest benefits from molecularly driven therapeutics. Patient-derived tumor organoids (PDTOs) represent an unmatched model to elucidate tumor resistance to therapy, due...
4.
Van Cutsem E, Danielewicz I, Saunders M, Pfeiffer P, Argiles G, Borg C, et al.
Br J Cancer
. 2022 Apr;
126(11):1548-1554.
PMID: 35440667
Background: Therapeutic options are limited in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy. The use of trifluridine/tipiracil plus bevacizumab (TT-B) in this setting was evaluated in...
5.
Bordonaro R, Calvo A, Auriemma A, Hollebecque A, Rubovszky G, Saunders M, et al.
ESMO Open
. 2021 Sep;
6(5):100270.
PMID: 34547581
Background: In preclinical studies trifluridine/tipiracil (FTD/TPI) plus oxaliplatin (Industriestrasse, Holzkirchen, Germany) sensitised microsatellite stable (MSS) metastatic colorectal cancer (mCRC) to anti-programmed cell death protein-1; the addition of oxaliplatin or bevacizumab...
6.
Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D, et al.
Ann Oncol
. 2021 Aug;
32(12):1496-1510.
PMID: 34411693
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of localised colon cancer was published in 2020. It...
7.
Foote M, Maron S, Cercek A, Argiles G, Rousseau B, Diaz Jr L
Ann Oncol
. 2021 Jun;
32(9):1188-1189.
PMID: 34139271
No abstract available.
8.
Argiles G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al.
Ann Oncol
. 2020 Jul;
31(10):1291-1305.
PMID: 32702383
No abstract available.
9.
Van Cutsem E, Danielewicz I, Saunders M, Pfeiffer P, Argiles G, Borg C, et al.
Ann Oncol
. 2020 Jun;
31(9):1160-1168.
PMID: 32497736
Background: We designed an open-label, noncomparative phase II study to assess the safety and efficacy of first-line treatment with trifluridine/tipiracil plus bevacizumab (TT-B) and capecitabine plus bevacizumab (C-B) in untreated...
10.
Isakoff S, Tabernero J, Molife L, Soria J, Cervantes A, Vogelzang N, et al.
Ann Oncol
. 2020 Mar;
31(5):626-633.
PMID: 32205017
Background: This phase Ib study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the oral AKT inhibitor ipatasertib and chemotherapy or hormonal therapy in patients with advanced or metastatic...